rare disease therapy – The Milli Chronicle

Friday, October 10, 2025

Latest:

Factual Version of a Story

Featured Health Lifestyle

NewsDesk Milli Chronicle October 10, 2025 biotech mergers 2025, biotechnology acquisition, drug development news, global biotech investments, healthcare innovation, J&J biotech expansion, J&J pharma growth, Janssen Biotech collaboration, Johnson & Johnson acquisition, Johnson & Johnson news, Johnson & Johnson strategy., medical research, peptide-based drugs, pharmaceutical innovation, polycythemia vera treatment, Protagonist stock surge, Protagonist Therapeutics, rare disease therapy, Rusfertide PTG-300, WSJ report

Johnson & Johnson Eyes Major Leap in Biotech: Talks Underway to Acquire Protagonist Therapeutics in Billion-Dollar Move

In a bold bid to expand its cutting-edge drug pipeline, Johnson & Johnson is reportedly in advanced talks to acquire

Latest Middle East and North Africa News

NewsDesk Milli Chronicle October 9, 2025October 9, 2025 advanced medical treatment, ALS clinical outcomes, ALS drug registration, ALS medication Saudi Arabia, ALS treatment, amyotrophic lateral sclerosis, antisense therapy, clinical trials, Health Sector Transformation Program, innovative therapies, Kingdom healthcare development, nerve cell protection, neurodegenerative disease, neurofilament reduction, orphan drugs, patient access, pharmaceutical innovation, protein misfolding therapy, Qalsody approval, rare disease therapy, rare genetic disease treatment, Saudi Arabia healthcare, Saudi FDA, Saudi medical innovation, Saudi patient care, Saudi rare disease patients, SOD1 gene, SOD1 protein reduction., Tofersen, vision 2030

Saudi FDA Approves Qalsody for ALS, Pioneering New Hope for Rare Disease Patients

Riyadh – In a landmark decision for rare disease treatment in Saudi Arabia, the Saudi Food and Drug Authority (SFDA)